Literature DB >> 25876463

Intra-articular delivery of anti-Hif-2α siRNA by chondrocyte-homing nanoparticles to prevent cartilage degeneration in arthritic mice.

Y Pi1, X Zhang1, Z Shao1, F Zhao1, X Hu1, Y Ao1.   

Abstract

Hypoxia-inducible factor-2α (Hif-2α) is a potential therapeutic target for osteoarthritis (OA), but the application of this target in the delivery of therapeutic agents to chondrocytes remains a challenge. A chondrocyte-targeting vector was constructed in a previous study to enhance transfection efficiency and specificity of chondrocytes in vivo. This study used vectors to deliver small-interfering RNA (siRNA) and silenced Hif-2α expression to prevent cartilage degeneration in OA-affected mice. After siRNA transfection was conducted by cartilage-targeting nanoparticles, the protein levels of Hif-2α, matrix metalloproteinases (MMP-13, -9), a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS-4, -5), vascular endothelial growth factor (VEGF), type X collagen and nuclear factor (NF)-κB in interleukin-1-beta (IL-1β)-stimulated chondrocytes were determined. Chondrocyte-targeting ability was also determined by fluorescein isothiocyanate (FITC)-labeled siRNA tracking under a confocal microscope. OA model was established by surgically destabilizing the knee joints of a mouse. Hif-2α siRNA was then delivered intra-articularly with nanoparticles in vivo. Cartilage degeneration and synovium inflammation in the knee joints were analyzed by histomorphometry. IL-1β levels in the synovial fluid were also measured by enzyme-linked immunosorbent assay. In vitro assay results showed that catabolic factors, including Hif-2α, MMP-13 and -9, ADAMTS-4, VEGF, collagen type X and NF-κB, were downregulated after Hif-2α-siRNA transfection by chondrocyte-targeting nanoparticles. In vivo assay results with FITC-labeled siRNA tracking also confirmed that nanoparticles promoted the local concentration and prolonged the retention time of siRNA in the cartilage. Histological analysis results confirmed that nanoparticle-mediated siRNA maintained cartilage integrity and alleviated synovium inflammation. IL-1β levels decreased after siRNA was silenced by nanoparticles. Thus, chondrocyte-targeting nanoparticles could deliver Hif-2α siRNA to cartilage and specifically inhibit the expression of catabolic proteins.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25876463     DOI: 10.1038/gt.2015.16

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  49 in total

1.  Risks and benefits of articular gene therapy.

Authors:  Marie-Christophe Boissier; Natacha Bessis
Journal:  Joint Bone Spine       Date:  2003-12       Impact factor: 4.929

Review 2.  Immune responses to gene therapy vectors: influence on vector function and effector mechanisms.

Authors:  N Bessis; F J GarciaCozar; M-C Boissier
Journal:  Gene Ther       Date:  2004-10       Impact factor: 5.250

3.  A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.

Authors:  Vijaykumar M Baragi; Gabriel Becher; Alison M Bendele; Ralf Biesinger; Harald Bluhm; Jürgen Boer; Hongbo Deng; Rory Dodd; Michael Essers; Tim Feuerstein; Brian M Gallagher; Christian Gege; Matthias Hochgürtel; Michael Hofmann; Andreas Jaworski; Lixia Jin; Andrew Kiely; Brian Korniski; Heiko Kroth; Darrell Nix; Bert Nolte; Dorothea Piecha; Timothy S Powers; Frank Richter; Matthias Schneider; Christoph Steeneck; Irving Sucholeiki; Arthur Taveras; Andreas Timmermann; Joshua Van Veldhuizen; Juergen Weik; Xinyuan Wu; Bing Xia
Journal:  Arthritis Rheum       Date:  2009-07

4.  Fibroblast growth factor 2 is an intrinsic chondroprotective agent that suppresses ADAMTS-5 and delays cartilage degradation in murine osteoarthritis.

Authors:  Shi-Lu Chia; Yasunobu Sawaji; Annika Burleigh; Celia McLean; Julia Inglis; Jeremy Saklatvala; Tonia Vincent
Journal:  Arthritis Rheum       Date:  2009-07

Review 5.  Articular cartilage repair.

Authors:  A P Newman
Journal:  Am J Sports Med       Date:  1998 Mar-Apr       Impact factor: 6.202

6.  A pivotal role for antigen-presenting cells overexpressing SOCS3 in controlling invariant NKT cell responses during collagen-induced arthritis.

Authors:  Sharon Veenbergen; Miranda B Bennink; Alsya J Affandi; Natacha Bessis; Jérôme Biton; Onno J Arntz; Wim B van den Berg; Fons A J van de Loo
Journal:  Ann Rheum Dis       Date:  2011-08-27       Impact factor: 19.103

7.  BRG1 and BRM chromatin-remodeling complexes regulate the hypoxia response by acting as coactivators for a subset of hypoxia-inducible transcription factor target genes.

Authors:  Johnny A Sena; Liyi Wang; Cheng-Jun Hu
Journal:  Mol Cell Biol       Date:  2013-07-29       Impact factor: 4.272

8.  STAT3 or USF2 contributes to HIF target gene specificity.

Authors:  Matthew R Pawlus; Liyi Wang; Aya Murakami; Guanhai Dai; Cheng-Jun Hu
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

9.  Hypoxia-inducible factor-2α regulates Fas-mediated chondrocyte apoptosis during osteoarthritic cartilage destruction.

Authors:  J-H Ryu; Y Shin; Y H Huh; S Yang; C-H Chun; J-S Chun
Journal:  Cell Death Differ       Date:  2011-08-26       Impact factor: 15.828

10.  Alterations in the vimentin cytoskeleton in response to single impact load in an in vitro model of cartilage damage in the rat.

Authors:  Frances M D Henson; Thea A Vincent
Journal:  BMC Musculoskelet Disord       Date:  2008-06-24       Impact factor: 2.362

View more
  23 in total

Review 1.  Technologies for controlled, local delivery of siRNA.

Authors:  Samantha M Sarett; Christopher E Nelson; Craig L Duvall
Journal:  J Control Release       Date:  2015-11-28       Impact factor: 9.776

Review 2.  Intra-articular drug delivery systems for joint diseases.

Authors:  Muhammad Farooq Rai; Christine Tn Pham
Journal:  Curr Opin Pharmacol       Date:  2018-04-03       Impact factor: 5.547

Review 3.  Applications of RNA interference in the treatment of arthritis.

Authors:  Muhammad Farooq Rai; Hua Pan; Huimin Yan; Linda J Sandell; Christine T N Pham; Samuel A Wickline
Journal:  Transl Res       Date:  2019-07-10       Impact factor: 7.012

4.  Tackling chondrocyte hypertrophy with multifunctional nanoparticles.

Authors:  M Bottini; A Magrini; B Fadeel; N Rosato
Journal:  Gene Ther       Date:  2016-04-14       Impact factor: 5.250

Review 5.  Cartilage-targeting drug delivery: can electrostatic interactions help?

Authors:  Ambika G Bajpayee; Alan J Grodzinsky
Journal:  Nat Rev Rheumatol       Date:  2017-02-09       Impact factor: 20.543

Review 6.  Overcoming barriers for intra-articular delivery of disease-modifying osteoarthritis drugs.

Authors:  Jingjing Gao; Ziting Xia; Helna B Mary; John Joseph; James N Luo; Nitin Joshi
Journal:  Trends Pharmacol Sci       Date:  2022-01-24       Impact factor: 14.819

Review 7.  [Research progress of nanomaterials for intra-articular targeted drug delivery in treatment of osteoarthritis].

Authors:  Lujie Zong; Qian Wu; Zhongchen Dong; Lixin Huang; Huilin Yang
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2022-07-15

Review 8.  Emerging potential of gene silencing approaches targeting anti-chondrogenic factors for cell-based cartilage repair.

Authors:  Andrea Lolli; Letizia Penolazzi; Roberto Narcisi; Gerjo J V M van Osch; Roberta Piva
Journal:  Cell Mol Life Sci       Date:  2017-04-22       Impact factor: 9.261

Review 9.  Bacteriophage-based biomaterials for tissue regeneration.

Authors:  Binrui Cao; Yan Li; Tao Yang; Qing Bao; Mingying Yang; Chuanbin Mao
Journal:  Adv Drug Deliv Rev       Date:  2018-11-16       Impact factor: 15.470

Review 10.  Osteoarthritis: Pathology, Mouse Models, and Nanoparticle Injectable Systems for Targeted Treatment.

Authors:  Derek T Holyoak; Ye F Tian; Marjolein C H van der Meulen; Ankur Singh
Journal:  Ann Biomed Eng       Date:  2016-04-04       Impact factor: 3.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.